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calorimetry; Me‒β‒CD, methyl–β–cyclodextrin; SC-CO2, supercritical carbon dioxide; SEM, 
rpm, revolutions per minute; Scanning electron microscopy; XRPD: X-ray powder 
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ABSTRACT 
The aim of this study was to enhance the apparent solubility and dissolution properties of 
flurbiprofen through inclusion complexation with cyclodextrins. Especially, the efficacy of 
supercritical fluid technology as a preparative technique for the preparation of flurbiprofen-
methyl–β–cyclodextrin inclusion complexes was evaluated. The complexes were prepared by 
supercritical carbon dioxide processing and were evaluated by solubility, differential 
scanning calorimetry, X-ray powder diffraction, scanning electron microscopy, practical 
yield, drug content estimation and in vitro dissolution studies. Computational molecular 
docking studies were conducted to study the possibility of molecular arrangement of 
inclusion complexes between flurbiprofen and methyl‒β‒cyclodextrin. The studies support 
the formation of stable molecular inclusion complexes between the drug and cyclodextrin in a 
1:1 stoichiometry. In vitro dissolution studies showed that the dissolution properties of 
flurbiprofen were significantly enhanced by the binary mixtures prepared by supercritical 
carbon dioxide processing. The amount of flurbiprofen dissolved into solution alone was very 
low with 1.11 ± 0.09% dissolving at the end of 60 min, while the binary mixtures processed 
by supercritical carbon dioxide at 45 °C and 200 bar released 99.39 ± 2.34% of the drug at 
the end of 30 min. All the binary mixtures processed by supercritical carbon dioxide at 45 °C 
exhibited a drug release of more than 80% within the first 10 min irrespective of the pressure 
employed. The study demonstrated the single step, organic solvent-free supercritical carbon 
dioxide process as a promising approach for the preparation of inclusion complexes between 
flurbiprofen and methyl–β–cyclodextrin in solid-state.  
 
Keywords: Dissolution rate; Flurbiprofen; Inclusion complexes; Methyl–β–cyclodextrin; 
Solubility; Supercritical fluid technology. 
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1. Introduction 
The water solubility of a drug is a key indicator for the solubility of drug molecules in the 
intestinal fluids and its contribution to bioavailability. The success of a pharmaceutical 
formulation relies on how effectively it makes the drug molecules available at the site of 
absorption. However, poor water solubility and the resulting poor oral bioavailability of most 
drugs available on the market has long been a problem to pharmaceutical scientists, as the 
dissolution is quite often the rate-limiting process in the absorption of a drug (Charman and 
Stella, 1991; Takagi et al., 2006). The ability to increase the water solubility of a drug is thus 
very important to enhancing its therapeutic efficacy. Several strategies to improve the water 
solubility and dissolution rate of poorly soluble drugs have been reported (Rudrangi et al., 
2011; Bontha et al., 2012; Weerapol et al., 2015; Kaialy and Al Shafiee, 2015; Aroso et al., 
2016; Jiang et al., 2016), among which is the inclusion complexation with cyclodextrins 
(Bandi et al., 2004; Cirri et al., 2005; Vega et al., 2013; Rudrangi et al., 2015a; Rudrangi et 
al., 2015b).  
Cyclodextrins are a family of non-reducing cyclic oligosaccharides composed of 
(α‒1,4)‒linked α‒D‒glucopyranose units. They possess a hydrophobic cavity and a 
hydrophilic exterior. The hydrophobic cavity can accommodate a poorly water-soluble drug, 
whilst the hydrophilic exterior facilitates high water solubility.  
Rudrangi and co-workers carried out the phase solubility studies of indomethacin and 
olanzapine formulated with Me‒β‒CD in phosphate buffer medium (pH 7.4) and de-ionised 
water (pH 7.1) at 37 °C, respectively. Rudrangi et al. (2015a) reported an AN-subtype phase 
solubility diagram with a stability constant of K1:1 = 167 M
-1 
for the
 
indomethacin-Me‒β‒CD 
complexes while Rudrangi et al. (2015b) reported an AL-subtype phase solubility diagram 
with a stability constant of K1:1 = 304 M
-1 
for the
 
olanzapine-Me‒β‒CD complexes. 
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Computational molecular docking studies of indomethacin and olanzapine with Me‒β‒CD 
were carried out by Rudrangi and co-workers using the Glide application. The binding 
affinity (GLIDE energy), van der Waals energy and docking score for inclusion of 
indomethacin in Me‒β‒CD were 27.880 kcal mol-1, -28.941 kcal mol-1 and -4.882 kcal mol-1, 
respectively (Rudrangi et al., 2015a), while the binding affinity, Van der Waals energy and 
docking score for inclusion of olanzapine in Me‒β‒CD were -24.13 kcal mol-1, -21.57 kcal 
mol
-1
 and -3.09 kcal mol-1, respectively (Rudrangi et al., 2015b). 
Flurbiprofen [2-(2-fluoro-4-biphenylyl)propionic acid] is a potent chiral non-steroidal anti-
inflammatory drug approved by the Food and Drug Administration for the treatment of 
rheumatoid arthritis and osteoarthritis (Davies, 1995). It also has profound analgesic effects 
and is indicated in the treatment of gingivitis and alveolar bone resorption in periodontitis 
(Heasman, P.A. et al., 1990). However, it has poor water solubility (5-13 µg mL
-1
) and 
dissolution rate (Anderson and Conradi, 1985), which limits both its therapeutic application 
and efﬁcacy. Hence, there is a need to enhance the water solubility and dissolution rate of 
flurbiprofen. 
Several formulation strategies have been reported to improve the solubility and dissolution 
rate of flurbiprofen, such as dry elixir (Kim and Yoon, 1995), solid dispersion (Habib et al., 
1998; Oh et al., 2011), salt formation (Gupta et al., 1997), microemulsion (Park et al., 1997; 
Ambade et al., 2008), inclusion complex with cyclodextrins (Tokumura et al., 2009; Li et al., 
2010) and cycloamyloses (Baek et al., 2011). 
Flurbiprofen has an afﬁnity for different cyclodextrins forming inclusion complexes. The 
favourable effect of natural β‒cyclodextrin (Muraoka et al., 2004; Cirri et al., 2005; 
Tokumura et al., 2009; Li et al., 2010; Baek et al., 2011) and its derivatives, such as 
hydroxypropyl‒β‒cyclodextrin (Govindarajan and Nagarsenker, 2005; Vega et al., 2013), 
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hydroxyethyl‒β‒cyclodextrin and methyl‒β‒cyclodextrin (Cirri et al., 2005) on its 
pharmaceutical properties has been previously reported. For example, Cirri et al. (2005) 
reported that flurbiprofen and methyl‒β‒cyclodextrin (Me‒β‒CD) complexes prepared in the 
1:1 molar ratio using kneading and co-evaporation techniques exhibit higher solubility and 
dissolution profiles than flurbiprofen alone or in a state of a physical mixture. In spite of their 
success, the complexes prepared by the co-evaporation and kneading methods required an 
organic solvent. Organic solvents are potentially hazardous and their presence in the final 
product (complexes) is highly undesirable and often requires energy-intensive drying steps 
involving a great deal of time to remove the residual solvent (Al-Marzouqi et al., 2007; Al-
Marzouqi et al., 2009). Hence, there is a need to avoid the use of organic solvents in the 
preparation of drug-cyclodextrin complexes. 
Pharmaceutical scientists relentlessly try to avoid the usage of toxic organic solvents and 
exchange those to more environmentally friendly alternatives with similar properties. One of 
those effective alternatives is the use of supercritical fluids. A supercritical fluid is a 
substance that exists above its critical point, where the phase boundaries diminish. Carbon 
dioxide is the most commonly employed supercritical fluid because of its low critical 
parameters. Supercritical carbon dioxide (SC-CO2) has provided an excellent green 
alternative to harmful organic solvents and the use of SC-CO2 processing technique in the 
preparation of drug-cyclodextrin complexes has been reported (York, 1999; Kompella and 
Koushik, 2001; Sunkara and Kompella, 2002; Türk et al., 2007; Lee et al., 2008; Rudrangi et 
al., 2015a; Rudrangi et al., 2015b). 
The application of supercritical carbon dioxide processing in the preparation of flurbiprofen-
Me‒β‒CD complexes has not yet been investigated. Therefore, the aim of this study was to 
evaluate supercritical fluid technology as a preparative technique for the preparation of 
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flurbiprofen-Me‒β‒CD inclusion complexes in solid-state. Inclusion complexes were 
prepared by physical mixing and SC-CO2 processing at various working (temperature and 
pressure) conditions. The prepared complexes were then characterized by solubility studies, 
differential scanning calorimetry (DSC), X-ray powder diffraction (XRD), scanning electron 
microscopy (SEM), practical yield, drug content evaluation and dissolution studies. 
2. Materials and methods 
2.1. Materials  
Flurbiprofen (≥ 98.5%, molecular weight: 244.26 g/mol) and Me‒β‒CD (average molecular 
weight: 1310 g/mol, extent of labeling: 1.6-2.0 mol CH3 per unit anhydroglucose) were 
purchased from Sigma-Aldrich (Gillingham, Dorset, UK). Ethanol was obtained from Fisher 
Scientiﬁc (Loughborough, UK). Carbon dioxide (99.9%) was obtained from BOC Ltd 
(Guildford, Surrey, UK). All reagents were used as received. 
2.2. Preparation of binary mixtures of flurbiprofen with Me‒β‒CD 
All binary mixtures were prepared in a 1:1 molar ratio of flurbiprofen to Me‒β‒CD. The 
processed samples were stored in desiccators until further use. 
2.2.1. Physical mixing 
Required quantities of flurbiprofen and Me‒β‒CD were accurately weighed and tumble-
mixed at 100 rpm for 15 min using a Turbula
®
 T2F mixer (Willy A. Bachofen AG – 
Maschinenfabrik, Muttenz, Switzerland). 
2.2.2. Supercritical carbon dioxide process 
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The SC-CO2 process was carried out in the static mode to achieve the inclusion of 
flurbiprofen in the Me‒β‒CD. The complexes were prepared using an extraction apparatus 
supplied by Thar Process Inc., USA as described in detail elsewhere (Rudrangi et al., 2015b). 
The physical mixtures of flurbiprofen and Me‒β‒CD were placed in a sample cell. Carbon 
dioxide was pumped from a cylinder via a cooling unit into the sample cell. The physical 
mixtures were processed at six different working conditions [35 °C/100 bar, 35 °C/150 bar, 
35 °C/200 bar, 45 °C/100 bar, 45 °C/150 bar and 45 °C/200 bar] in order to study the 
influence of temperature and pressure on the inclusion complex formation.  
2.3. Analysis of the prepared binary mixtures  
Having prepared these model complexes by supercritical carbon dioxide processing, the next 
aim is to compare the physical properties with those of complexes prepared using physical 
mixing. 
2.3.1. Solubility studies 
Saturation solubility of flurbiprofen was measured in triplicate by adding excess amounts of 
the drug to 10 mL of deionised water in sealed glass containers. The solutions were agitated 
for 72 hours at 25 °C. The solutions were then ﬁltered (0.45 µm ﬁlter pore size) and assayed 
for drug concentration by ultra-violet spectroscopy (Cary 100 UV-vis, Agilent Technologies, 
USA) after dilution.  
Phase solubility diagram was obtained according to the method reported by Higuchi and 
Connors (1965). Samples were prepared by adding excess flurbiprofen (in an amount above 
its solubility), to a 10 mL deionised water containing successively increasing concentrations 
(0, 2.5, 5, 10, 12.5, 15, 20 and 25 × 10
-3
 M) of Me‒β‒CD, in sealed glass containers. The 
solutions were agitated (200 rpm) at 25 °C for 72 hours. Following equilibrium, the solutions 
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were then ﬁltered and assayed for drug concentration by UV spectroscopy as described 
above. Phase-solubility diagram was represented as the concentration of total dissolved 
flurbiprofen against the concentration of Me‒β‒CD. The binding constant (K1:1) for 
flurbiprofen-Me‒β‒CD complexes was calculated from the slope of the curve. 
2.3.2. Differential scanning calorimetry (DSC) analysis 
DSC analysis of flurbiprofen, Me‒β‒CD and the flurbiprofen-Me-β-CD complex systems 
was carried out using a FP-90 central processor (Mettler-Toledo, LLC, UK). The instrument 
was calibrated using indium as the reference material. For each sample, about 5 mg of each 
sample was accurately weighed, hermetically sealed in an aluminium pan, and then heated 
from 50 to 150 °C at a heating rate of 10 °C min
-1
. The control study was carried out to 
investigate the effect of SC-CO2 processing on flurbiprofen alone. 
2.3.3. X-ray powder diffraction (XRPD) analysis 
X-ray powder diffractograms of flurbiprofen, Me‒β‒CD and the flurbiprofen-Me‒β‒CD 
complex systems were obtained on a D8 Advance X-ray Diffractometer (Bruker, Germany) 
in theta–theta Bragg–Brentano geometry using reflection mode. Data were collected between 
2-40
o
 2θ, with a step size of 0.006o and a time of 0.5 s per step using Cu Kα radiation. A 
control study was carried out to investigate the effect of SC-CO2 processing on flurbiprofen 
alone. 
The degree of crystallinity (% crystallinity) of the flurbiprofen-Me‒β‒CD complex systems 
was determined using the amorphous subtraction method as reported previously (Rudrangi et 
al., 2015a). 
2.3.4. Practical yield 
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The efficiency of a processing method used for the preparation of inclusion complexes can be 
measured by determining the practical yield of the binary systems. The percentage practical 
yield of the binary systems was determined using the following equation: 
                     
                                     
                   D      C            
      
2.3.5. Evaluation of the flurbiprofen content 
Flurbiprofen-Me‒β‒CD binary system, equivalent to 10 mg of the drug, was accurately 
weighed and dispersed in ethanol (10 mL), in which both the drug and cyclodextrin are 
soluble. The mixture was agitated (100 rpm) at 25 + 0.5 °C for 30 min and the resultant 
solution was filtered (0.45 µm ﬁlter pore size) and assayed for the concentration of total 
flurbiprofen by UV spectroscopy after dilution. Determination of the flurbiprofen content in 
the complexes allows the verification that there is no loss of flurbiprofen during the 
(complex) preparation process. 
2.3.6. In vitro dissolution studies 
In vitro dissolution studies of flurbiprofen from all drug-carrier binary systems, and for 
flurbiprofen alone, were conducted in triplicate using USP Type II paddle method (Hanson 
G2 Vision
®
 Classic 6, Chatsworth, CA) with deionised water as the dissolution medium. The 
samples, corresponding to 1000 mg of flurbiprofen were dispersed into 900 mL of the 
dissolution media maintained at 25 + 0.5 °C and stirred at 100 rpm. Aliquots (5 mL) were 
withdrawn and filtered (0.45 µm ﬁlter pore size) at the speciﬁed time intervals (2, 5, 10, 20, 
30 and 60 min) and the drug concentration was determined by UV spectroscopy at a λmax of 
246 nm. The same volume of fresh medium was added to the vessel and the correction for the 
cumulative dilution was calculated. The parameters used to characterize the dissolution 
curves were the percentage of flurbiprofen dissolved at 30 min, and the dissolution efficiency 
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at 30 and 60 min. The dissolution efficiency was calculated according to Khan (1975). 
DE30min was calculated from the area under the dissolution curve at 30 min and expressed as a 
percentage of the area of the rectangle described by 100% dissolution in the same time of the 
total amount added. 
2.3.7. Molecular docking studies 
Molecular docking studies were conducted to study the possibility of molecular arrangement 
of inclusion complexes between flurbiprofen and Me‒β‒CD. Molecular docking studies of 
flurbiprofen into Me‒β‒CD were conducted using Glide (grid-based ligand docking) 
application implemented in the Maestro 9.3 software package (Schrodinger, LLC, New York, 
USA, 2012) as reported earlier (Rudrangi et al., 2015b). Docked flurbiprofen and Me‒β‒CD 
complexes were visualised and molecular surface complex pictures were generated using 
Maestro. 
3. Results and discussions 
3.1. Solubility studies 
The amount of flurbiprofen dissolved at 25 °C was 12.29 ± 1.05 µg mL
-1 
and 30.68 ± 
0.5 µg mL
-1 
after 1 h and 24 h, respectively. No further improvement was observed in drug 
solubility after 24 h.  
Cirri et al. (2005), Li et al. (2010) and Baek et al. (2011) reported a drug solubility of 40 µg 
mL
-1
,
 
10.45 ± 3.22 µg mL
-1 
and
 
5.12 ± 1.22 µg mL
-1 
in water at 25 °C after 24 h, 120 h and 
168 h, respectively. Herzfeldt and Kummel (1983) reported a drug solubility of 8 µg mL
-1 
and 
31.2
 
µg mL
-1 
in pH 1.2 and 7.5 buffered solutions at 25 °C after 24 h, respectively. Varma 
and Pandi (2005) reported a drug solubility of 48.2 µg mL
-1 in water at 27 °C after 72 h.  
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The solubility of flurbiprofen increased in a linear fashion with the concentration of 
Me‒β‒CD (Fig. 1), forming AL-subtype complexes (presumably 1:1 stoichiometry). The 
binding constant of the complexes (K1:1 = 16856 ± 1244 M
-1
) was calculated from the slope of 
the curve. Similar phase solubility profile was reported for flurbiprofen-Me‒β‒CD complexes 
in water by Cirri et al. (2005). The authors reported the stability constant values of K1:1 = 
11570 M
-1
 and
 
9660 M
-1
 in unbuffered water (pH ≈ 4.5) at 25 °C and 37 °C, respectively, and 
the values of K1:1 = 1480 M
-1
 and
 
1085 M
-1
 in phosphate buffer (pH 5.5) at 25 °C and 37 °C, 
respectively. 
3.2. Solid-state analyses 
The DSC traces of the unprocessed flurbiprofen and SC-CO2 processed flurbiprofen (Fig. 2a) 
showed sharp melting endotherms at 118.26 °C and 118.27 °C, respectively, confirming that 
SC-CO2 process has not altered the crystallinity of the drug, as further substantiated by 
XRPD analysis (Fig. 2b). Similar results were reported by Rudrangi et al. (2015a and b) for 
indomethacin and olanzapine when processed with SC-CO2.  
The DSC traces and X-ray powder diffractograms of flurbiprofen, Me‒β‒CD and 
flurbiprofen-Me‒β‒CD (1:1 molar) binary systems prepared by physical mixing and SC-CO2 
processing are presented in Figs. 3a and 3b, respectively. 
The DSC trace of Me‒β‒CD was characterized by a broad endothermic event between 60 °C 
and 120°C ascribed to its dehydration (Banchero et al. (2013); Rudrangi et al. (2015a)). The 
XRPD pattern of Me‒β‒CD displayed two broad features at 11° and 18° indicating its 
predominately-amorphous nature. 
The DSC traces of the binary mixtures prepared by physical mixing or SC-CO2 processing (at 
35 °C/100 bar, 35 °C/150 bar, 35 °C/200 bar, 45 °C/100 bar and 45 °C/150 bar) showed 
endothermic peaks of reduced intensity  in comparison to the unprocessed pure flurbiprofen. 
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This was confirmed by XRPD analysis, which showed the physical mixture of flurbiprofen 
and Me‒β‒CD to have similar diffraction pattern to that of the respective individual 
components but with a reduction in the intensity of drug peaks. The reduced intensity of the 
DSC endothermic peaks and the reduced XRPD intensities for the drug suggest an 
incomplete inclusion of flurbiprofen in the cavity of Me‒β‒CD. The DSC trace of the binary 
mixtures prepared by SC-CO2 processing at 35 °C/150 bar and 35 °C/200 bar showed broad 
endothermic peaks of drug shifted to higher temperatures, potentially attributable to the 
partial inclusion of the drug into cyclodextrin (Marques et al. (1990)).  
A complete disappearance of the flurbiprofen melt peak was observed in the inclusion 
complexes prepared by SC-CO2 processing at 45 °C/200 bar, indicating interactions between 
flurbiprofen and Me‒β‒CD and the formation of inclusion complex with partially crystalline 
nature , as suggested by Charoenchaitrakool et al. (2002) and Rudrangi et al. (2015a and 
2015b). This was supported by XRPD analysis, which showed the complexes prepared by 
SC-CO2 processing at 35 °C/100 bar, 35 °C/150 bar, 35 °C/200 bar, 45 °C/100 bar and 45 
°C/150 bar to have a considerable diminution of the diffraction peaks. A close analysis of the 
diffraction patterns of these samples and their comparison with that of the pure flurbiprofen 
showed an increase in the intensity of the drug peak at 2θ equal to 31.73°. This change may 
be attributed to a partial recrystallization of the drug during SC-CO2 processing or the 
formation of the inclusion complex between flurbiprofen and Me‒β‒CD as suggested by He 
and Li (2009) in the case of borneol and Me‒β‒CD complexes. 
A complete disappearance of the drug peaks but the retention of two broad features similar to 
that of the pure Me‒β‒CD was observed in the diffraction pattern of the complexes prepared 
by SC-CO2 processing at 45 °C/200 bar suggesting a complete complexation between 
flurbiprofen and Me‒β‒CD. 
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The decrease in the degree of crystallinity of the drug was observed in the following order: 
SC-CO2 45°C/200 bar > SC-CO2 45°C/150 bar > SC-CO2 45°C/100 bar > SC-CO2 35°C/200 
bar > SC-CO2 35°C/150 bar > SC-CO2 35°C/100 bar > Physical mixing.  
3.3. Practical yield 
The percentage practical yield of all the binary mixtures is tabulated in Table 1. It was 
observed that all the binary mixtures prepared by SC-CO2 processing resulted in the loss of 
mass of the complexes to some extent. The practical yields of the binary mixtures prepared 
by SC-CO2 processing were above 96% (w/w).  
3.4. Evaluation of the flurbiprofen content 
The percentage drug content of the binary mixtures ranged from 94.59 ± 0.31% to 97.88 ± 
0.18% (Table 2), which is within the acceptable range (85-115%) provided in the United 
States Pharmacopoeia 29 (USP 29, 2006). 
3.5. Dissolution studies 
All the binary systems exhibited better dissolution profiles than the drug alone (Fig. 4). This 
enhancement can be attributed to the surfactant-like properties of cyclodextrin and the 
formation of inclusion complexes between flurbiprofen and Me‒β‒CD in the solid-state (Lin, 
and Kao, 1989; Guyot et al., 1995). The highest improvement of the drug dissolution 
properties was obtained from the binary mixture prepared by SC-CO2 processing at 45 
°C/200 bar, followed by the mixtures processed at 45 °C/150 bar and 45 °C/100 bar. 
The parameters used to characterize the dissolution curves were the percentage of 
flurbiprofen dissolved at 30 min, and the dissolution efficiency at 30 and 60 min. The percent 
drug dissolved (DP) is defined as the amount of drug dissolved at certain time, t, while the 
dissolution efficiency (DE) is defined as the area under the dissolution curve up to a certain 
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time, t, expressed as a percentage of the area of the rectangle described by 100 % dissolution 
at the same time. DE was calculated according to Khan (1975). 
The percent flurbiprofen dissolved at 30 min (DP30min) and the dissolution efficiency at 30 
min (DE30 min) is presented in Table 3. The amount of flurbiprofen released from drug alone 
was very low with 1.11 ± 0.09% dissolving at the end of 60 min, whereas the binary mixture 
obtained by physical mixing exhibited a significant increase in the dissolution with 72.47 ± 
3.23% of flurbiprofen dissolved at the end of 30 min. 
It is also evident from the results (Fig. 4 and Table 3) that the degree of the improvement in 
the dissolution rate is dependent on not only the method of preparation but also the 
processing conditions used for the preparation of complexes. All the SC-CO2 processed 
systems exhibited higher apparent drug dissolution than the physical mixture systems; 
however, considerable differences were observed in the degree of enhancement. The binary 
mixtures prepared by SC-CO2 processing at 35 °C/100 bar exhibited a faster drug release 
compared to the mixtures processed at 45 °C/200 bar after 30 min (74.9 ± 3.0% versus 99.4 ± 
2.3%). All the binary mixtures prepared by SC-CO2 processing at 45 °C exhibited a drug 
release of more than 80% within the first 10 min, irrespective of the pressure employed. Both 
the temperature and pressure showed a positive influence on the dissolution of the 
flurbiprofen-Me‒β‒CD inclusion complexes. At all pressures (100 bar, 150 bar and 200 bar) 
when the temperature was increased (from 35 °C to 45 °C), the dissolution of the complexes 
increased. Moreover, the increase of dissolution became more apparent at higher pressures. 
The instantaneous dissolution properties offered by all the binary mixtures are attributable to 
the improvement in drug wettability due to the high aqueous solubility (greater than 2000 mg 
mL
-1 
as reported by Banchero et al., 2013) and the superior complexing properties of 
Me‒β‒CD (Cirri et al., 2005).  
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3.6. Docking studies 
The single best pose of flurbiprofen docked in the cavity of Me‒β‒CD is presented in Fig. 5. 
Flurbiprofen is coloured in green and the figure has a molecular surface (grey with a reddish 
tint in the depths), mesh surface of the hydrophilic area (cyan mesh) and the hydrophobic 
area (orange mesh at the mid depth of Me‒β‒CD). The figure shows the binding of 
flurbiprofen in the cavity of Me‒β‒CD through phenyl group presumably due to its 
hydrophobicity. Secondary hydrogen bonding exists between the oxygen atom of Me‒β‒CD 
and the hydrogen atom of flurbiprofen. The binding affinity (GLIDE energy), van der Waals 
energy and docking score for the inclusion of flurbiprofen in Me‒β‒CD are -20.660 kcal mol-
1
, -20.303 kcal mol
-1 
and
 
-4.259 kcal mol
-1
,
 
respectively. 
Conclusions 
A novel solid inclusion method for the complexation flurbiprofen into methyl–β–cyclodextrin 
using supercritical carbon dioxide carrier was shown. The possibility of flurbiprofen-methyl–
β–cyclodextrin interactions of different efficiencies in the solid-state was demonstrated. 
Products obtained by the supercritical carbon dioxide processing exhibited the highest 
apparent drug dissolution followed by the physical mixture and the drug alone. All the 
products processed by SC-CO2 at 45 °C offered more than 80% drug release within the first 
10 min irrespective of the pressure employed. The method proposed involves no toxic solvent 
residues, thus the products obtained provide minimal side effects in humans, compared to 
those obtained by other techniques that require the use of organic solvents. The preliminary 
data suggests that the complexation of flurbiprofen with methyl–β–cyclodextrin will lead to 
better therapeutic efficacy. 
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LEGENDS FOR FIGURES 
 
Fig. 1. Phase solubility studies of flurbiprofen with increasing concentrations of Me‒β‒CD at 
25 °C and in deionised water. 
Fig. 2. Control study: DSC traces (a) and X-ray powder diffractograms (b) of unprocessed 
flurbiprofen and flurbiprofen processed with SC-CO2 at 45 °C/200 bar. 
Fig. 3. DSC traces (a) and X-ray powder diffractograms (b) of flurbiprofen, Me‒β‒CD and 
flurbiprofen-Me‒β‒CD (1:1 molar) binary systems prepared by physical mixing and SC-CO2 
processing (the flurbiprofen thermogram has been reduced by a factor of 5). 
Fig. 4. Dissolution rate profiles of flurbiprofen and flurbiprofen-Me‒β‒CD binary systems 
prepared by physical mixing and SC-CO2 processing. 
Fig. 5. Representation of the complex between Me‒β‒CD (orange) and flurbiprofen (green) 
obtained by molecular docking (1:1 stoichiometry). 
 
 
TABLES 
 
Table 1. Percentage practical yield of flurbiprofen-Me‒β‒CD binary systems 
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Table 2. Drug content in flurbiprofen-Me‒β‒CD binary systems (mean ± SD, n=3). 
Method Practical yield (%)  
Physical mixing 99.5 ± 0.2 
Supercritical carbon dioxide  processing 
35 °C/100 bar 
35 °C/150 bar 
35 °C/200 bar 
45 °C/100 bar 
45 °C/150 bar 
45 °C/200 bar 
 
98.4 ± 0.7 
97.8 ± 0.2 
98.4 ± 0.6 
97.6 ± 0.2 
96.3 ± 0.1 
97.9 ± 0.8 
Method Drug content (%)  
Physical mixing 94.59 ± 0.31 
  
25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supercritical carbon dioxide  processing 
35 °C/100 bar 
35 °C/150 bar 
35 °C/200 bar 
45 °C/100 bar 
45 °C/150 bar 
45 °C/200 bar 
 
97.88 ± 0.18 
96.62 ± 0.21 
95.51 ± 0.37 
95.63 ± 0.42 
98.34 ± 0.16 
96.58 ± 0.63 
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Table 3. Percent flurbiprofen dissolved (DP) at 30 min and dissolution efficiency (DE) at 30 
min from flurbiprofen and flurbiprofen-Me‒β‒CD binary systems prepared by physical 
mixing and SC-CO2 processing. 
Product DP30 (%) DE30min (%) 
Flurbiprofen 1.1 ± 0.1 0.8 ± 0.2 
Physical mixing 72.5 ± 3.2 64.8 ± 2.7 
Supercritical carbon dioxide processing 
35 °C/100 bar 74.9 ± 3.0 65.2 ± 2.8 
35 °C/150 bar 77.8 ± 3.2 68.2 ± 2.8 
35 °C/200 bar 86.5 ± 3.1 76.5 ± 2.8 
45 °C/100 bar 90. 8 ± 3.3 80.8 ± 3.0 
45 °C/150 bar 96.2 ± 3.2 85.5 ± 2.8 
45 °C/200 bar 99.4 ± 2.3 88.38 ± 2.8 
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